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Abstract
Background: Dual diagnosis is common in Borderline Personality Disorder (BPD), one of the most common being
Substance Use Disorder (SUD). Previous studies have shown that general psychiatric management (GPM) was
effective in reducing borderline symptoms.
In the present study, we tested whether the short GPM was as effective in the BPD + SUD as in the BPD
group.
Methods: We analysed a group of 99 patients presenting a BPD. 51 of these patients presented a SUD. The
BPD group and the BPD + SUD group received a manual-based short variant of the GPM treatment. Previous
studies have shown that a 10-session version of GPM was effective in reducing borderline symptoms at the
end of the treatment (Psychother Psychosom 83:176–86, 2014).
Results: We found no significant difference in the reduction of general symptoms, which diminished in both
groups. The specific borderline symptoms were also reduced in both groups, but there was a slightly higher
reduction of the borderline symptoms in the SUD group. The therapeutic alliance progressed positively in all
groups. Moreover, the alliance increased more over time in the SUD group.
Conclusion: The short variant of GPM seems to be effective in BPD treatment independently from the presence of
SUD. Therefore, this treatment could be an effective entry-level treatment for patients with dual diagnosis as well as
patients with BPD only. Further studies are needed to confirm efficacy and long-term outcome.
Trial registration: The trial was registered at ClinicalTrial.gov (identifier NCT01896024).
Background
Borderline personality disorder (BPD) is a common mental
disorder. It is associated with high suicide rates and severe
functional impairment [1, 2]. Patients suffering from BPD
have high rates of co-morbid mental disorders, amongst
them substance use disorders (SUD) are very common.
According to a systematic review, about 38–57% of BPD
patients also have a SUD diagnosis [3]. On the other hand,
between 5 and 32% of people with SUD are estimated to
meet the criteria for BPD [4, 5].
Some studies reported more severe SUD profile for
patients with BPD [6]. Studies show inconsistent findings
concerning a possible aggravation of BPD symptoms by
SUD [7]. Overall people with this co-morbid condition
seem to have higher rates of depression and lower levels
of functioning [8, 9].
The higher levels of psychosocial impairment, more
severe psychopathology and the increased rates of suicidal
behavior of the co-morbid BPD with SUD population
presents a considerable challenge for mental health
services [10–12].
BPD is a chronic illness for which several evidence
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these are long term very specialized and costly treat-
ments which limits treatment accessibility [13–15].
Only few randomized trials with small study populations
assessed treatment programs in co-morbid patients [7, 16].
Treatment retention is an issue for some patients pre-
senting a SUD, some analysis show earlier drop-out [17, 18]
and some do not [19, 20]. Especially women drop out
more likely when presenting higher levels of psychiatric
symptoms [21]. In order to offer full treatment cycles
to difficult to engage patients, shorter treatment packages
could be helpful.
As for other psychiatric disorders short-term treatment
models [22, 23] allow more patients to benefit from therapy
and to make better use of limited resources. An effective
treatment for BPD is the general psychiatric management
(GPM) developed by Gunderson [24]. Generalist mental
health clinicians can deliver this treatment after a short
introductory course. It focuses on psycho-education, in-
formed management of medication and co-morbid disor-
ders. The aim is to improve the patient’s functionality and
quality of life. Various studies reported that the model or
versions of it are effective for BPD [25, 26] but so far no
studies have specifically examined its effect when treating a
BPD population with substance use disorder in a short-
term time frame. This is the objective of the present study.
Short-term treatments are interesting for patients with
SUD as these patients are generally more difficult to en-
gage in long-term psychotherapy treatments due to the
chronic and relapsing nature of SUD [27, 28].
Paris [29] and Chanen and Thompson [30] suggest a
stepped-care model in which different evidence-based
treatment models for BPD by stepwise progression for
different clinical phases [31]. According to this model,
short-term treatment are useful and cost-effective first
steps strategies to help BPD patients manage their symp-
toms in order to improve their functionality [31]. When
they are more organized and can enter more in depth
psychological treatment, they can be referred to special-
ists for psychotherapy. This approach is of high interest
for patients with SUD as the mental health practitioner
for SUD can easily apply psychiatric interventions with-
out having to address the patient to a BPD specialized
therapist. Often patients with SUD are not stable enough
to regularly attend fixed group meetings like for DBT
and are therefore often excluded from such programs. A
study by Black shows that patients with higher baseline
severity showed greater improvement after short-term
treatment [32]. As mentioned above the cost-effectiveness
of GPM is an important advantage over long-term treat-
ments by specialized practitioners. The shorter GPM
consists of weekly sessions which requires less intensive
training. The ability of this model to address more patients
with a proven effective treatment can therefore reduce dir-
ect and indirect costs caused by BPD [33]. Direct costs are
due to hospital admissions, emergency room visits and
primary care visits and indirect costs are those caused
by other medical and social problems related to lower in-
come, marriages and child-rearing difficulties [34, 35].
In spite of such promising rationale for the use of
GPM with people with co-morbid BPD and SUD, we ex-
pect a negative impact of the co-morbidity on the GPM
treatment outcomes given the increased severity associ-
ated with this co-morbidity in comparison to BPD alone
[10–12]. The fact that these patients often show a higher
symptom level [36] and more psychiatric comorbidities
is usually associated with the conclusion that they would
show worse outcome in any treatment. The higher risk
of treatment drop-out due to active substance use and a
possibly less strong therapeutic alliance could be a rea-
son for this negative outcome.
On the other hand, treating patients with GPM could
actually make patients with BPD and SUD feel better
understood as this treatment focuses more largely on
their problems and does not focus solely on SUD and
associated symptoms. This might help therapists adapt
better to the patients’ needs and could actually improve
the therapeutic alliance. Also, SUD does not always nega-
tively influence therapeutic alliance [37]. The.
To our knowledge no short-term program has been
studied for patients with co-morbid BPD and SUD.
Aims of the study
The aim of the study at hand is to compare the impact
of a 10-session version of a GPM treatment [24, 38] on
patients with BPD and patients with BPD and a co-morbid
SUD concerning treatment process and outcome.
Hypotheses
1) We assume that the presence of a co-morbid substance
use disorder diminishes the symptom change found
over ten sessions of psychiatric treatment.
2) We assume that the presence of a co-morbid sub-
stance use disorder diminishes the quality of the
therapeutic alliance over the course of the first ten
sessions of therapy.
Methods
Design
In the present study we examined the role of a co-morbid
substance use disorder on the process and outcome of a
10-session version of an APA-informed psychiatric treat-
ment (“good psychiatric management”; GPM [24]) for BPD.
The present study is a secondary analysis of two ran-
domized controlled studies, both originally examining the
identical research question and using identical procedures,
which justifies their combination for the present study
[39, 40]. Together the two studies randomized a total of
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114 (29 plus 85, respectively) patients with BPD to two
conditions based on a 10-session treatment for BPD: a
short version of the GPM in the first condition, and the
same treatment augmented with the motive-oriented
therapeutic relationship (MOTR) [41]. Adherence to GPM
model was excellent for both conditions [42]. Kramer, Kolly
et al. [40] found significant symptom reduction for both
conditions on all measures, between condition analyses
revealed between-group effects varying between d = 0.06
for specific borderline symptom and d = 0.64 for general
symptom outcome reduction. Adding MOTR to GPM
showed a greater reduction of general problems. However
no additional borderline symptom reduction was found in
the MOTR group.
The reporting and discussion of missing data in this
study, along with analyses of treatment drop-out, are
provided in the original publications [39, 40].
In these former studies the impact of SUD was not
specifically examined. In the present research we exam-
ine the impact of SUD on the treatment outcome.
In consideration of the lack of differences in outcome
measures for GPM and GPM+MOTR in the previous
studies we consider it as acceptable to combine the two
groups in order to improve our sample size to maximize
power. Both groups received the same GPM 10-sessions
treatment.
In order to assess differences in alliance and outcomes
between patients with BPD and patient with comorbid
SUD, we differentiated between (a) patients with a co-
morbid alcohol use disorder (AUD), (b) patients with
other SUD (OSUD; all drugs included), (c) patients with
both AUD and OSUD, and (d) patients with no SUD co-
morbidity.
Patients
A total of N = 114 patients were considered for analysis
in the present sample. Because of missing diagnostic infor-
mation (4 in the pilot study and 11 in the main study), 99
patients were finally included in the present analysis. All
patients were treated at a French speaking outpatient
university clinic. All patients presented a DSM-IV diag-
nosis of BPD. The ethnic composition represented the
consulting psychiatric population in public European
clinical services (85% Caucasian). Diagnoses were estab-
lished by trained clinicians using the Structured Clinical
Interview for DSM-IV Axis II Disorders [43], along with
the Mini Neuropsychiatric Interview for co-morbid
psychiatric disorders [44]. The reliability of the DSM-
IV axis II diagnosis was satisfactory; κ = 0.81. Reliability
was analyzed with independent ratings of video-taped
SCID-II diagnostic interviews on a randomly chosen
10% of all patients included [40]. The addiction diagno-
sis was based on chart review using DSM-IV criteria.
The diagnoses were made by the psychiatrist treating
the patient. SUD diagnostic accuracy was routinely super-
vised by a senior psychiatrist. In total, n = 20 (20%) pre-
sented a co-morbid alcohol use disorder, n = 10 (10%)
presented another SUD, n = 21 (21%) presented alcohol
and another SUD concomitantly, the remaining patients,
n = 48 (48%) are without any co-morbid SUD (see Table 1).
The drop-out rate was 25% for patients without SUD, 40%
for patients with alcohol use disorder, 0% for patients with
another SUD and 24% for patients with alcohol and co-
morbid SUD.
Therapists
In total, N = 24 therapists (13 of them treated 3 patients or
less, and 11 more than 3 patients) conducted the treat-
ments of the patients in this study. All the therapists were
trained in the clinical procedures related to the psychiatric
management of BPD in 10 sessions before the study began.
The therapists were residents in psychiatry for an overall
mean of 2.5 years (at least one year).
Treatment
A short-term treatment program held in 10 sessions based
on the principles of the good psychiatric management for
BPD (GPM) was used in this study. The therapists con-
ducted the treatment according to a manual focusing on
GPM treatment principles: [1] establishment of a reliable
psychiatric diagnoses, including co-morbidities and other
problem areas, and communication of this information to
the patient; [2] synthesis of the psychiatric anamnesis; [3]
identification of the treatment focus; [4] definition of
short-term objectives and enhancement of treatment mo-
tivation; [5] working on treatment-interfering problems,
and [6] formulation of attachment-based core conflictual
themes. In general, the patients received one session per
week; if necessary, short-term inpatient treatment and
psychopharmacological treatment was added.
Instruments
Outcome Questionnaire – 45.2 (OQ-45), is a self-report
questionnaire which assesses results from psychotherapy
using 45 items. It includes a global score and three sub-
scores: symptomatic level, interpersonal relationships
and social role [45]. These items are rated on a Likert-
scale ranging between 1 (never) and 4 (always). This
questionnaire is widely used and has been translated and
validated in French [46]. This scale was given measured
at intake and discharge. Cronbach’s alpha at intake of
the present sample was .91.
Borderline Symptom List (BSL-23), [47], which is also a
self-report questionnaire. This measures specific border-
line symptomatology using 23 items. The specific items
are measured using a Likert-type scale ranging from 0
(absent) to 4 (clearly present) and an overall mean score
is retained. It is a shortened version of the BSL-95,
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which reportedly has very good psychometric properties.
Similar results were found for the short version. The
present study used the French translation approved by
the authors. Cronbach’s alpha for the current sample
was .95.
Working Alliance Inventory – short form (WAI-short
version), which is a self-report questionnaire, of 12
items assessing the different dimensions of therapeutic
alliance, the bond between patient and therapist and
therapy collaboration agreement (task and goals) [48].
The items are measured on a Likert-type scale ranging
from 1 (never) to 7 (always); an overall sum score is com-
puted [49]. The questionnaire measuring the therapeutic
alliance was given to the patient after each session.
Procedure
The responsible Ethic Committee cleared the study. After
an intake interview, the patients meeting inclusion criteria
were met by a program related researcher who explained
the study to them. After written informed consent, these
patients then received 10 sessions of GPM according to
the manual. During the treatment, they answered the OQ-
45 and the BSL-23 at intake and discharge.
Statistical analyses
Characteristics at baseline are presented within four groups
of patients: BPD with no substance or alcohol use disorder,
BPD with alcohol use disorder only, BPD with substance
use disorder only and BPD with both substance and alcohol
use disorder. In order to compare these four groups,
Fisher’s exact test (instead of Chi-square due to the
small sample size) or ANOVA or Kruskal-Wallis rank sum
test were performed.
In order to test hypothesis 1) stating that the SUD
lessened the symptom decrease over the course of treat-
ment, we first conducted two paired-sample t-tests on
the score of OQ-45 and BSL-23, the grouping variable
being presence of SUD. As a measure of effect size,
which is a magnitude of the difference between groups
or time points, Cohen’s d were also computed [50]. Ac-
cording to Cohen [50], d smaller than 0.20 is considered
as a small effect, between 0.20 and 0.50 as a medium ef-
fect size and greater than .50 as large effect size. And
second, we conducted two parallel Linear Mixed-effects
Models [51] with the score of OQ-45 and BSL-23 as the
dependent variables, SUD (None vs. Any SUD) and
Time (intake vs. discharge) as the independent variables
as well as age, gender and therapeutic condition (BPM
vs. BPM +MOTR) as covariates. This type of model is
suitable for correlated measurements [52] as it accounts
for the lack of independence of the observations due to
the fact subjects are measured more than once.
In order to test hypothesis 2) stating that the SUD
lessened the alliance level and progression over the first
10 sessions of treatment, we also ran a Linear Mixed-
effects Models with the alliance measured by the WAI
as the outcome, SUD (None vs. Any SUD) and Session
number as the independent variables as well as age, gen-
der and therapeutic condition (BPM vs. BPM+MOTR)
as covariates. At least 2 measurement occasions are re-
quired for a patient to be included in the analyses.
Statistical analyses were performed using R 3.3.0 [53].
Regarding the Linear mixed-effects models, the ‘nlme’ R
package [54] has been used [51, 52].
Results
Preliminary analyses (see Table 1)
N = 99 patients were included in the present analysis. In
total, n = 68 (69%) were female. The average age was
32.2 years (s.d. = 10.6, median = 30, range:19–55), n = 50
(50%) had never been married, n = 30 (30%) were mar-
ried and n = 46 (46%) were separated or divorced. The
employment rate was very low. n = 75 (74%) were un-
employed, n = 7 (7%) were working in a protected activ-
ity, n = 6 (6%) were had a part-time job and n = 10 (10%)
were working full-time. n = 74 (73%) completed the
treatment, in the alcohol use disorder (AUD) group the
number of completers was slightly lower than in the
other groups, n = 12 (60%). Further details of each sam-
ple can be found in Table 1.
Characteristics at baseline
No between-group effects reached statistical significance
for all variables at baseline except for number of axis I
diagnoses. Contrary to expectation, post-hoc test revealed
that patients without substance use had significantly more
axis I diagnosis (cf. Table 1). Also for the outcome vari-
ables, no between group differences at intake (OQ-45,
BSL and WAI) were statically significant.
Since no statistical differences were found between
those four groups, except for axis 1 (difference None vs.
Other SUD) and axis 2 (difference None vs. Alcohol)
diagnoses, Alcohol and substance use disorder have been
merged in order to create two groups only: BPD without
any SUD, N= 48 and BPD with SUD, N = 51.
First hypothesis: Effect of SUD on symptoms over the
course of treatment
OQ-45 – Questionnaire
The OQ-45 was measured at intake and discharge. It as-
sesses results from psychotherapy including symptom-
atic level, interpersonal relationships and social role.
Overall, OQ-45 improved between intake and discharge
(mean and s.d. at intake = 95.2±23.7, mean and s.d. at
discharge = 81.9±24.0, mean difference = − 13.23, paired
t-test: t = − 6.35, df = 98, p < 0.001;d = 0.56). When compar-
ing Any SUD with no SUD/None there was no significant
difference between OQ-45 at intake and at discharge (mean
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difference and sd for no SUD= − 14.1±22.6, mean differ-
ence and sd for Any SUD= − 12.6±19.3, independent t-test
on mean difference by groups, t = − 0.369, df = 97, p-value
= 0.71;d = 0.07).
When controlling for potential confounders (cf. Table 2),
results regarding Any SUD vs no SUD/None, as well as
evolution over time are the same. Interestingly, the GPM+
MOTR condition is significantly associated with an im-
provement of symptoms over time.
BSL-23 – Questionnaire
The BSL-23 which measures the number of specific border-
line symptoms was given at intake and discharge. Regarding
the number of specific borderline symptoms (BSL-23), only
61 patients were included in the analysis since this ques-
tionnaire was added later in the study. There was an overall
improvement (mean and s.d. at intake = 1.8±0.9, mean and
s.d. at discharge = 1.5±1.0, mean difference = − 0.26, paired
t-test: t = − 2.544, df = 60, p < 0.014; d = 0.28) with a better
improvement within the Any SUD group (mean difference
and sd for no SUD = − 0.07±0.81, mean difference and
sd for Any SUD = − 0.49±0.78, independent t-test on
mean difference by groups, t = 2.074, df = 59, p-value =
0.04;d = 0.53).
When controlling for potential confounders (cf. Table 2),
there is a significant interaction between Time and SUD
co-morbidity, in the sense that the improvement is better
within the Any SUD group (cf. Fig. 1). In this case,
GPM +MOTR condition was not significantly associ-
ated with a change of BSL-score over time.
Second hypothesis: Effects of SUD on the therapeutic
alliance
The analyses on the possible impact of SUD on the
therapeutic alliance were done on a sub-sample of n =
82 patients, due to n = 17 patients with missing alliance
data. For the computation of the progression, n = 75 pa-
tients were included. In order to be included in this lat-
ter analysis, the patients needed at least two assessment
points of the therapeutic alliance (n = 7 patients only
had one data point for the therapeutic alliance).
When taking into account the intra-subject variability
of the alliance, substantiated as the session-by-session
alliance progression over the course of treatment (cf.
Table 3), we found the following picture. The progres-
sion of the therapeutic alliance was positively signifi-
cant in the analyses (regression coefficient: cf. Table 3).
Moreover, the therapeutic alliance increases more over
time in the Any SUD category comparing to the None
category (regression coefficient: cf. Table 3). There is no
statistically significant difference between GPM+MOTR
and GPM condition (regression coefficient: cf. Table 3).
Discussion
As mentioned previously SUD and BPD are highly co-
morbid and the present study aims to compare the impact
of a GPM treatment [24, 38] on patients with BPD and
patients with BPD and a co-morbid SUD.
In the initial studies by Kramer and Kolly [39, 40] the
effect of adding motive-orientated therapeutic relationship
(MOTR) to GPM was analyzed regarding symptom reduc-
tion and therapeutic alliance. Both groups showed a signifi-
cant reduction of general symptoms (OQ-45) and specific
borderline symptoms (BSL-23). The individualizing ap-
proach in the MOTR group did not have an additional
effect on the reduction of specific borderline symptoms
but did have an effect on the decrease of the general
and interpersonal problems. As GPM is already aimed
at specifically reducing these, we did not expect much
room for improvement on the borderline symptoms.
The therapists in the MOTR group rated a higher alliance
progression. It is possible that the treatment period was
Table 2 Effects of SUD on symptoms over the course of treatment, results from the linear mixed-effects models
OQ-45 BSL
β Std. Error p-value β Std. Error p-value
Age 0.54 0.20 0.0091 0.03 0.01 0.0233
Gender (Male vs. Female) −2.67 4.59 0.5631 − 0.13 0.24 0.5793
Any SUD vs. None 6.03 7.41 0.4181 0.46 0.38 0.2363
GPM +MOTR vs. GPM 15.94 7.45 0.0351 0.20 0.39 0.6053
Time (Intake or Discharge) −7.76 3.60 0.0332 0.01 0.19 0.9674
Any SUD x Time 0.46 4.07 0.9102 − 0.44 0.21 0.0374
GPM +MOTR x Time − 12.22 4.07 0.0032 − 0.12 0.21 0.5574
SUD Substance Use Disorder, GPM General Psychiatric Management, MOTR Motive-oriented therapeutic relationship, OQ-45 Outcome Questionnaire – 45.2, BSL Bor-
derline Symptom List
Significant p-values are in bold
1T-test with 94 degrees of freedom
2T-test with 96 degrees of freedom
3T-test with 57 degrees of freedom
4T-test with 58 degrees of freedom
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too short for the patients to percept this improved alliance
due to its focus on patient’s motives.
In our secondary analysis we examined the effect of al-
cohol and other substance use disorders on the therapy
outcome after 10 sessions of GPM. As explained earlier
consistent results were found when differentiating in 4
groups (AUD, Other SUD, AUD and SUD, None). In
order to increase power, we only report the results from
the Any SUD and None groups.
We hypothesized that SUD would diminish the symptom
change found over 10 sessions of psychiatric treatment.
After 10 sessions, we observed a significant reduction of
borderline symptoms according to the BSL-23 in both
groups. However, in contradiction with our hypotheses, in
the group of patients presenting a SUD the borderline
symptom reduction was more important than in the group
without this co-morbid condition (See Fig. 1), moderate ef-
fect size on BSL-23.
This is in line with the observation made by Black et
al. [32]. Patients with higher baseline severity scores im-
prove more than those with lower scores at baseline
after a short-term intervention. Our Any SUD group
also showed higher baseline severity for BSL the before
the intervention and significantly higher improvement
on BSL. Possibly patients with more important symp-
toms show a faster short-term remission which may not
be maintained over a longer period. This group of pa-
tients is often more stigmatized and perhaps the fact of
them receiving special attention during therapy might
motivate them to engage more. This could explain the
greater symptom improvement. This however shoes that
patients with comorbid SUD can benefit equally from
treatment as patients without SUD. Further studies are
needed to analyze these effects in short- and long-term
outcomes.
There was no significant difference found in the delta
OQ-45 measures for the two groups.
Again, this is an important finding as we hypothesized
that the improvements would be less important in the
Any SUD group. This result again shows that the inter-
vention was also as effective independently from the
presence of SUD.
Overall the therapeutic alliance progressed over the
course of the therapy in all groups. In the group of pa-
tients with Any SUD the alliance increased more over
time than in the other categories. This is an important
finding and disproves our hypothesis.
This means that we cannot prove that SUD affects the
therapeutic alliance. As before, a possible explanation
could be the effect of TAU on SUD resulting in patients
with SUD being able to focus on the therapy. It is also
shown in other studies, that patients with SUD show
high treatment alliance in individual therapy [55]. Again
this shows that patients suffering from SUD can benefit
from the GPM treatment and should not be excluded
from treatment programs. As shown in other studies
with cocaine dependent patients, drug use severity alone
does not predict the alliance or time in treatment [37].
Table 3 Effects of SUD on the therapeutic alliance, results from
the linear mixed-effects models
WAI
β Std. Error d.f.a t-value p-value
Age −0.02 0.15 70 −0.16 0.871
Gender (Male vs. Female) −1.97 3.43 70 −0.57 0.568
Any SUD vs. None −3.43 3.21 70 −1.01 0.288
GPM +MOTR vs. GPM −3.03 3.28 70 −0.92 0.360
Session 0.52 0.25 410 2.11 0.036
AnySUD x Session 0.71 0.28 410 2.55 0.011
GPM +MOTR x Session 0.08 0.28 410 0.27 0.786
SUD Substance Use Disorder, GPM General Psychiatric Management, MOTR
Motive-oriented therapeutic relationship, WAI Working Alliance Inventory
Significant p-values are in bold
adegrees of freedom
Fig. 1 Adjusted change of the BSL from the linear mixed-effects models
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Strong alliance can predict better treatment retention
with less drop-out and better drug outcome for some
therapies (individual manual based drug counseling and
brief psychodynamic therapy), in CBT high alliance is
linked to shorter stay in treatment [55]. The ability to
improve treatment retention with GPM may be a good
preparation for long-term treatment if necessary.
The short-term approach to treatment can easily be
applied to BPD patients with SUD by their health care
practitioner to help diminish the intensity of central bor-
derline problems and improve their functionality. If neces-
sary at a later stage, these patients might be addressed for
more in-depth treatment of BPD for which SUD is often a
limiting factor.
There were a number of limitations for this study. We
do not have any long-term outcome measures to prove
that the effect of the treatment stays the same for both
groups. These are secondary analysis, so we have fewer
details on the evaluation of co-morbid SUD, such as se-
verity of SUD. The number of patients for each group
was limited. Furthermore, between substance use dis-
order analyses were not carried out due to the limited
number of patients. Our outcome measures were self-
reported which is subject to responder bias. Although
the drop-out rate was moderate in our patient groups, it
has to be considered as a possible limitation. It is a
known that patients with SUD have a higher risk of
treatment drop-out and perhaps complementary offers
are needed to reduce this risk in order for patients being
able to benefit even more from treatments such as GPM
[56]. Another limitation for this study was the combin-
ation of two different treatment groups GPM and GPM
+MOTR even though MOTR did not show a significant
additional effect in previous studies.
Conclusions
The short variant of GPM seems to be an effective treat-
ment option for patients with BPD independently from
the presence of SUD. Therefore, this treatment could be
an effective entry-level treatment for patients with dual
diagnosis and a possible preparatory step before starting
more specific long-term treatment. It is important and
possible to treat the BPD in patients with SUD. Treating
the two disorders simultaneously could help enhance
outcomes in both areas. Further studies are needed to
confirm efficacy and long-term outcome.
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